| Name | Title | Contact Details |
|---|
Yokohama TWS, part of The Yokohama Rubber Co., Ltd., is a leader in designing and producing tire and wheel solutions to drive a sustainable future for Agriculture, Construction, Material Handling and Two-Wheeler markets. Our 6,600+ workforce on 5 continents, 14 state-of-the-art manufacturing facilities, OEM partnerships, digital technologies, field tests and sustainable product sourcing all work together to bring our customers worldwide the latest in tire innovations and services that enhance their performance and improve their businesses. Combining value, safety and ease, Yokohama TWS offers a multi-brand portfolio which includes the Trelleborg, Mitas, Maximo, and Cultor brands and Interfit custom fitting services. Our brands are supported by a vast network of local specialists, to bring tailor-made services that evolve with our customers and their businesses, wherever they are. We pair localized expertise with the power of our global reach; staying close to the communities and companies where people need us most. Indeed, for Yokohama TWS, fostering a company-wide culture of sustainability focused on planet, innovative products and support for people and places where we operate is simply the right thing to do. We are equally committed to becoming a sustainability leader in our industry. We aim to minimize the impact that our global operations and supply chain has on the environment. And to achieve this, we empower our employees to make a difference. They work as one to drive positive change throughout our company, our products, and our industry. Innovation – Technology – Sustainability – Service – Caring for our communities: Our people take ownership to deliver on this promise every day. This is how, for over a century, Yokohama TWS has and will continue to bring specialty tire and wheel solutions – engineered for the future.
Public Risk Innovation, Solutions, and Management, PRISM, is a member-directed risk sharing pool of counties and public entities committed to providing risk coverage programs and risk management services.
Established in 2015, India based NODWIN Gaming nourishes the dynamic gaming & esports ecosystem both domestically and internationally. Fueled by innovative ideas and passion, the company brings expertise and solutions in all of the aspects within the broad label of the esports industry. From tournaments & events, through influencers & content, to marketing & activations. You name it. NODWIN Gaming makes it happen. The fresh perspectives presented by highly skilled team members and management engage and inspire players, spectators, and brands. NODWIN Gaming is constantly hungry and focused on making a global impact. The company invests in emerging markets around the world. Currently, its expansion has reached South Africa, South Asia and the UAE, but it wont stop there.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Financial Serivices Company